Binding of aminoalkylphosphorothioate radioprotective drugs to rodent tissue proteins

John C. Livesey, Zdenka Grunbaum, Kenneth Krohn

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The formation of protein mixed disulfides which influences the pharmacodynamics of the phosphorothioate radioprotective drugs WR2721 [S-2-(3-aminopropyl)aminoethylphosphorothioic acid, Ethiofos] and WR3689 [S-2-(3-methylaminopropylamino)ethylphosphorothioic acid] and their metabolites was investigated. WR3689-derived thiols and disulfides bound to rat serum protein to about 45 and 40% of the total drug in the incubation when present at a 400 μM concentration. Metabolites of WR2721 were nearly indistinguishable from the corresponding metabolites of WR3689 in their mixed disulfide binding propensity. Mixed disulfide formation was saturable; binding sites on bovine albumin or rat serum protein amounted to 0.15 and 2.4 μmol/mg protein respectively. The sum of all WR3689 metabolites (when measured by NMR spectroscopy) was reduced to the same degree as drug binding, suggesting that a portion of the bound drug was not NMR observable. Approximately 2-4 nmol WR3689-thiol/mg protein was bound to homogenates of mouse tissues (liver, kidney, lung, brain, and serum) when incubated in vitro, whereas after in vivo injection drug binding appeared to be limited more by drug distribution than by the capacity for mixed disulfide formation.

Original languageEnglish (US)
Pages (from-to)1807-1812
Number of pages6
JournalBiochemical Pharmacology
Volume39
Issue number11
DOIs
StatePublished - Jun 1 1990
Externally publishedYes

Fingerprint

Radiation-Protective Agents
Disulfides
Rodentia
Metabolites
Tissue
S-2-(3-methylaminopropylamino)ethylphosphorothioic acid
Pharmaceutical Preparations
Proteins
Sulfhydryl Compounds
Rats
Blood Proteins
Pharmacodynamics
Amifostine
Liver
Nuclear magnetic resonance spectroscopy
Albumins
Brain
Magnetic Resonance Spectroscopy
Binding Sites
Nuclear magnetic resonance

ASJC Scopus subject areas

  • Pharmacology

Cite this

Binding of aminoalkylphosphorothioate radioprotective drugs to rodent tissue proteins. / Livesey, John C.; Grunbaum, Zdenka; Krohn, Kenneth.

In: Biochemical Pharmacology, Vol. 39, No. 11, 01.06.1990, p. 1807-1812.

Research output: Contribution to journalArticle

Livesey, John C. ; Grunbaum, Zdenka ; Krohn, Kenneth. / Binding of aminoalkylphosphorothioate radioprotective drugs to rodent tissue proteins. In: Biochemical Pharmacology. 1990 ; Vol. 39, No. 11. pp. 1807-1812.
@article{8183bd829c7b4c27bf73a4efae3f5a80,
title = "Binding of aminoalkylphosphorothioate radioprotective drugs to rodent tissue proteins",
abstract = "The formation of protein mixed disulfides which influences the pharmacodynamics of the phosphorothioate radioprotective drugs WR2721 [S-2-(3-aminopropyl)aminoethylphosphorothioic acid, Ethiofos] and WR3689 [S-2-(3-methylaminopropylamino)ethylphosphorothioic acid] and their metabolites was investigated. WR3689-derived thiols and disulfides bound to rat serum protein to about 45 and 40{\%} of the total drug in the incubation when present at a 400 μM concentration. Metabolites of WR2721 were nearly indistinguishable from the corresponding metabolites of WR3689 in their mixed disulfide binding propensity. Mixed disulfide formation was saturable; binding sites on bovine albumin or rat serum protein amounted to 0.15 and 2.4 μmol/mg protein respectively. The sum of all WR3689 metabolites (when measured by NMR spectroscopy) was reduced to the same degree as drug binding, suggesting that a portion of the bound drug was not NMR observable. Approximately 2-4 nmol WR3689-thiol/mg protein was bound to homogenates of mouse tissues (liver, kidney, lung, brain, and serum) when incubated in vitro, whereas after in vivo injection drug binding appeared to be limited more by drug distribution than by the capacity for mixed disulfide formation.",
author = "Livesey, {John C.} and Zdenka Grunbaum and Kenneth Krohn",
year = "1990",
month = "6",
day = "1",
doi = "10.1016/0006-2952(90)90129-9",
language = "English (US)",
volume = "39",
pages = "1807--1812",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Binding of aminoalkylphosphorothioate radioprotective drugs to rodent tissue proteins

AU - Livesey, John C.

AU - Grunbaum, Zdenka

AU - Krohn, Kenneth

PY - 1990/6/1

Y1 - 1990/6/1

N2 - The formation of protein mixed disulfides which influences the pharmacodynamics of the phosphorothioate radioprotective drugs WR2721 [S-2-(3-aminopropyl)aminoethylphosphorothioic acid, Ethiofos] and WR3689 [S-2-(3-methylaminopropylamino)ethylphosphorothioic acid] and their metabolites was investigated. WR3689-derived thiols and disulfides bound to rat serum protein to about 45 and 40% of the total drug in the incubation when present at a 400 μM concentration. Metabolites of WR2721 were nearly indistinguishable from the corresponding metabolites of WR3689 in their mixed disulfide binding propensity. Mixed disulfide formation was saturable; binding sites on bovine albumin or rat serum protein amounted to 0.15 and 2.4 μmol/mg protein respectively. The sum of all WR3689 metabolites (when measured by NMR spectroscopy) was reduced to the same degree as drug binding, suggesting that a portion of the bound drug was not NMR observable. Approximately 2-4 nmol WR3689-thiol/mg protein was bound to homogenates of mouse tissues (liver, kidney, lung, brain, and serum) when incubated in vitro, whereas after in vivo injection drug binding appeared to be limited more by drug distribution than by the capacity for mixed disulfide formation.

AB - The formation of protein mixed disulfides which influences the pharmacodynamics of the phosphorothioate radioprotective drugs WR2721 [S-2-(3-aminopropyl)aminoethylphosphorothioic acid, Ethiofos] and WR3689 [S-2-(3-methylaminopropylamino)ethylphosphorothioic acid] and their metabolites was investigated. WR3689-derived thiols and disulfides bound to rat serum protein to about 45 and 40% of the total drug in the incubation when present at a 400 μM concentration. Metabolites of WR2721 were nearly indistinguishable from the corresponding metabolites of WR3689 in their mixed disulfide binding propensity. Mixed disulfide formation was saturable; binding sites on bovine albumin or rat serum protein amounted to 0.15 and 2.4 μmol/mg protein respectively. The sum of all WR3689 metabolites (when measured by NMR spectroscopy) was reduced to the same degree as drug binding, suggesting that a portion of the bound drug was not NMR observable. Approximately 2-4 nmol WR3689-thiol/mg protein was bound to homogenates of mouse tissues (liver, kidney, lung, brain, and serum) when incubated in vitro, whereas after in vivo injection drug binding appeared to be limited more by drug distribution than by the capacity for mixed disulfide formation.

UR - http://www.scopus.com/inward/record.url?scp=0025288389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025288389&partnerID=8YFLogxK

U2 - 10.1016/0006-2952(90)90129-9

DO - 10.1016/0006-2952(90)90129-9

M3 - Article

C2 - 2160821

AN - SCOPUS:0025288389

VL - 39

SP - 1807

EP - 1812

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 11

ER -